The association of sickle cell trait (SCT) and hereditary spherocytosis (HS) has been reported in only 18 patients. Three of these 18 patients experienced splenic infarct or acute splenic sequestration. We report here a 46-year-old African-American male, the oldest reported case to date, who experienced episodes of hemolysis and severe left upper quadrant pain for the past 26 years. The patient had compensated hemolysis with splenomegaly. A CT scan of the abdomen revealed a large infarct in the spleen. The diagnosis of SCT was confirmed with isoelectric focusing, cation exchange and reverse-phase HPLC. The presence of a silent, interacting globin variant as the cause of hemolysis and sickling in the spleen was ruled out by sequencing of the α1-, α2- and β-globin genes. The diagnosis of HS was established by an osmotic fragility test. The interaction of HS and SCT leads to RBC dehydration with increased MCHC and intracellular Hb S concentration presumably favoring intrasplenic sickling and resultant splenic infarcts and sequestration as seen in this case.

Keywords:
Sickle cell trait, Spherocytosis, hereditary, Splenic infarction, Splenic sequestration
1.
Smith EW, Conley CL: Clinical features of genetic variants of sickle cell disease. Bull Johns Hopkins Hosp 1954;94:289–318.
2.
Yang YM, Donell C, Wilborn W, Goodman SR, Files B, Moore RB, Mohandas N, Mankad VN: Splenic sequestration associated with sickle cell trait and hereditary spherocytosis. Am J Hematol 1992;40:110–116.
3.
Santiano J, Bonaime V, Cheraitia Y, Robert R, Galacteros F: Splenic infarction revealing heterozygous sickle cell trait with spherocytosis. Arch Pediatr 1997;4:1262–1263.
4.
Babiker MA, El Seed FA: A family with sickle cell trait and hereditary spherocytosis. Scand J Haematol 1984;33:54–58.
5.
Rodriguez S, Leikin S, Bullock WH, Booker C: Hereditary spherocytosis and sickle cell trait in the negro. J Pediatr 1966;68:589–593.
6.
Whitaker A, Windmiller J, Vietti T, Sartain P: Hereditary spherocytosis associated with hemolytic anemia. J Pediatr 1963;63:65–68.
7.
De Torregrosa MV, Ortiz A, Vargas D: Sickle cell spherocytosis associated with hemolytic anemia. Blood 1956;11:260–265.
8.
Cohen F, Zuelzer WW, Neel JV, Robinson AR: Multiple inherited erythrocyte abnormalities in an American negro family: Hereditary spherocytosis, sickling, and thalassemia. Blood 1959;14:816–827.
9.
Martin WW, Kough RH, Branche GC: Hereditary spherocytosis-sicklemia in the negro: Case report and study of a negro family having multiple instances of hereditary spherocytosis. Blood 1959;14:688–693.
10.
Jones B, Klingberg WG, Louis S: Hemoglobin S-hereditary spherocytosis. Two case reports. J Pediatr 1959;54:375–378.
11.
Maurer HS, Vida LN, Honig GR: Homozygous sickle cell disease with coexistent hereditary spherocytosis in three siblings. J Pediatr 1972;80:235–242.
12.
Warkentin TE, Barr RD, Ali MAM, Mohandas N: Recurrent acute splenic sequestration crisis due to interacting genetic defects: Hemoglobin SC disease and hereditary spherocytosis. Blood 1990;75:266–270.
13.
Thompson RB, Robertson MG: Three inherited intraerythrocytic defects: Hereditary spherocytosis, Hb S and Hb C. Acta Haematol 1964;32:233–238.
14.
Kark JA, Posey DM, Schumacher HR, Ruehle CJ: Sickle cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987;317:781–787.
15.
Kutlar A, Huisman THJ: The detection of hemoglobinopathies; in Hommes F (ed): Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. New York, Wiley, 1991, chap 30, p 519.
16.
Kutlar F, Kutlar A, Huisman THJ: Separation of normal and abnormal hemoglobin chains by reverse phase high performance liquid chromatography. J Chromatogr 1986;357:147–153.
17.
Poncz M, Solowiejczyk D, Harpel B, Mory E, Schwarz E, Surrey S: Construction of human gene libraries from small amounts of peripheral blood: Analysis of β-like globin genes. Hemoglobin 1982;6:27–36.
18.
Kutlar F, Milner PF, McKie KM, Wilson JB, Kutlar A: A new approach to the detection of -α3.7 deletion by PCR (abstract). 21st Annual Meeting of the National Sickle Cell Disease Program, Mobile 1996, p 31.
19.
Molchanova TP, Pobedimskaya DD, Huisman THJ: The differences in quantities of the α2 and α1 globin variants in heterozygotes. Br J Haematol 1994;88:300–306.
20.
Dacie JV, Lewis SM: Practical Haematology. New York, Churchill Livingstone, 1991, p 195.
21.
Lane PA, Githens HJ: Splenic syndrome at mountain altitudes in sickle cell trait. JAMA 1985;253:2251–2254.
22.
LaCelle PL: pH in the mouse spleen and its effects on erythrocyte flow properties. Blood 1974;44:910.
23.
Murphy JR: The influence of pH and temperature on some physical properties of normal erythrocytes from patients with hereditary spherocytosis. J Lab Clin Med 1967;69:758–775.
24.
Lauf PK, Bauer J, Adragna NC, Fujise H, Zade-Oppen AM. Rye KH, Delpire E: Erythrocyte K-Cl cotransport: Properties and regulation. Am J Physiol 1992;263:C917–C932.
25.
Griggs RC, Weisman RJ, Harris JW: Alterations in osmotic and mechanical fragility related to in vivo erythrocyte aging and splenic sequestration in hereditary spherocytosis. J Clin Invest 1960;39:89–101.
© 2003 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.